Kilitch Drugs to sell Ethiopian arm for $14 million
In short
Kilitch Drugs plans to sell its Ethiopian arm for $14 million. The company says the money will be used for growth in India, debt repayment, and its main drug business.
This could help Kilitch Drugs focus on its core work. The report does not say when the sale will finish or if any approvals are still pending.
What the reporting says
Kilitch Drugs plans to divest its Ethiopian arm for $14 million, according to the publisher summary. The company says the sale will help it reallocate capital toward higher-growth opportunities in India, repay debt, and expand its core pharmaceutical business. The reporting does not say when the deal will close or whether regulatory approvals are still needed.
Why it matters
Kilitch Drugs is set to divest its Ethiopian business for $14 million, based on the publisher summary. The company says the proceeds will be used to support higher-growth opportunities in India, reduce debt, and expand its core pharmaceutical operations. The report does not give timing or closing conditions, so the near-term impact is a planned portfolio shift rather than a completed transaction.